PH12014501029A1 - Pharmaceutical compositions comprising glitazones and nrf2 activators - Google Patents
Pharmaceutical compositions comprising glitazones and nrf2 activatorsInfo
- Publication number
- PH12014501029A1 PH12014501029A1 PH1/2014/501029A PH12014501029A PH12014501029A1 PH 12014501029 A1 PH12014501029 A1 PH 12014501029A1 PH 12014501029 A PH12014501029 A PH 12014501029A PH 12014501029 A1 PH12014501029 A1 PH 12014501029A1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical compositions
- nrf2 activators
- glitazones
- nrf2
- activators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11194292 | 2011-12-19 | ||
| EP12004652 | 2012-06-21 | ||
| US201261663761P | 2012-06-25 | 2012-06-25 | |
| US13/654,632 US20130158077A1 (en) | 2011-12-19 | 2012-10-18 | Pharmaceutical compositions |
| PCT/EP2012/074915 WO2013092269A1 (en) | 2011-12-19 | 2012-12-10 | Pharmaceutical compositions comprising glitazones and nrf2 activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014501029A1 true PH12014501029A1 (en) | 2014-06-23 |
Family
ID=48610741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2014/501029A PH12014501029A1 (en) | 2011-12-19 | 2012-12-10 | Pharmaceutical compositions comprising glitazones and nrf2 activators |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US20130158077A1 (OSRAM) |
| EP (1) | EP2793876B1 (OSRAM) |
| JP (1) | JP6132850B2 (OSRAM) |
| KR (2) | KR20220139414A (OSRAM) |
| CN (1) | CN103998035B (OSRAM) |
| AR (1) | AR089301A1 (OSRAM) |
| AU (4) | AU2012358420B9 (OSRAM) |
| BR (1) | BR112014014809A2 (OSRAM) |
| CA (1) | CA2859635C (OSRAM) |
| CL (1) | CL2014001639A1 (OSRAM) |
| EA (1) | EA201400729A1 (OSRAM) |
| ES (1) | ES2959111T3 (OSRAM) |
| HK (1) | HK1200711A1 (OSRAM) |
| IL (1) | IL233134A0 (OSRAM) |
| MX (2) | MX2014007254A (OSRAM) |
| PH (1) | PH12014501029A1 (OSRAM) |
| SG (1) | SG11201403241XA (OSRAM) |
| WO (1) | WO2013092269A1 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| ES2679918T3 (es) | 2010-02-18 | 2018-08-31 | Vtv Therapeutics Llc | Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| CA2894653A1 (en) * | 2012-12-11 | 2014-06-19 | Metabolic Solutions Development Company, Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| PT2970101T (pt) | 2013-03-14 | 2018-10-04 | Alkermes Pharma Ireland Ltd | Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| EP3110793B1 (en) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| WO2015130998A1 (en) | 2014-02-28 | 2015-09-03 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| US10034868B2 (en) | 2014-11-04 | 2018-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prevention and the treatment of rapidly progressive glomerulonephritis |
| WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| KR101704410B1 (ko) | 2015-07-22 | 2017-02-22 | 대구가톨릭대학교산학협력단 | 사파논 a를 함유하는 심혈관질환의 예방 및 치료용 조성물 |
| US20180318246A1 (en) * | 2015-10-28 | 2018-11-08 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| PT3411361T (pt) * | 2016-02-03 | 2021-01-29 | Rigel Pharmaceuticals Inc | Compostos ativadores de nrf2 e suas utilizações |
| CN106389457A (zh) * | 2016-11-30 | 2017-02-15 | 胡立志 | PPAR‑γ激动剂在制备治疗脱发药物中的应用及治疗脱发的药物 |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US12274703B2 (en) | 2017-12-21 | 2025-04-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| CN108685903B (zh) * | 2018-07-05 | 2019-10-18 | 陕西师范大学 | 鼠尾草酚在制备防治实验性自身免疫性脑脊髓炎药物的应用 |
| WO2020094767A1 (en) | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| KR20210096162A (ko) * | 2018-11-27 | 2021-08-04 | 쿄와 기린 가부시키가이샤 | 의약 조성물 |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| CN111606828B (zh) * | 2019-02-22 | 2023-07-28 | 浙江海正药业股份有限公司 | (E)-α,β-不饱和酰胺化合物的晶型及其制备方法和用途 |
| CN109846867A (zh) * | 2019-03-29 | 2019-06-07 | 北京中医药大学 | 花姜酮用于制备抗心肌缺血的药物的用途 |
| WO2021024057A1 (en) * | 2019-08-05 | 2021-02-11 | International Business Machines Corporation | Polylysine polymers with antimicrobial and/or anticancer activity |
| CN110279866B (zh) * | 2019-08-12 | 2021-06-29 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品 |
| CN110613712B (zh) * | 2019-10-22 | 2021-06-29 | 上海交通大学医学院附属第九人民医院 | 中药组合物及其在治疗血管炎症和内皮损伤中的应用 |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| CN113244221B (zh) * | 2020-02-12 | 2022-10-25 | 华东师范大学 | 双甲基鼠尾草酚在制备治疗恶病质疾病的药物中的应用 |
| US20250002436A1 (en) * | 2020-02-24 | 2025-01-02 | Robert F. Hofmann | Naphthoquinone-based chalcone derivatives and uses thereof |
| US20230134760A1 (en) * | 2020-03-04 | 2023-05-04 | Hongbing Wang | Car and nrf2 dual activator agents for cyclophosphamide-based and doxorubicin-based treatments of cancer |
| EP4117785A4 (en) * | 2020-03-13 | 2024-04-17 | Marc J. Simard | METHODS OF TREATMENT OF MULTIPLE SCLEROSIS |
| CN111574437A (zh) * | 2020-06-22 | 2020-08-25 | 上海长车生物科技有限公司 | (e)-3-芳杂环基丙-2-烯酸衍生物及其制备和用途 |
| CN111529514A (zh) * | 2020-06-23 | 2020-08-14 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 一种特丁基对苯二酚的应用及治疗椎间盘退变的药物 |
| JP2023541192A (ja) * | 2020-09-14 | 2023-09-28 | トリテルペノイド・セラピューティクス・インコーポレイテッド | ＣＤＤＯ－２Ｐ－Ｉｍ及びＣＤＤＯ－３Ｐ－Ｉｍの類似体 |
| US20250134845A1 (en) * | 2022-02-15 | 2025-05-01 | Emory University | Fumaric Acid Esters, Inhalation Administration Methods, Pharmaceutical Uses and Compositions |
| KR20230123323A (ko) | 2022-02-16 | 2023-08-23 | 대구대학교 산학협력단 | 알릴 이소티오시아네이트(Allyl isothiocyanate)를 유효성분으로 포함하는 골 대사성 질환의 예방, 개선 또는 치료용 조성물 |
| CN114414809B (zh) * | 2022-03-28 | 2022-06-21 | 中元伯瑞生物科技(珠海横琴)有限公司 | 用于诊断尘肺病的生物标志物的应用 |
| EP4580612A1 (en) | 2022-09-02 | 2025-07-09 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| CN117137897B (zh) * | 2023-10-31 | 2024-02-13 | 中国中医科学院中药研究所 | 索法酮在制备用于预防/治疗银屑病的药物中的应用 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US807113A (en) | 1905-03-27 | 1905-12-12 | Frederick O Dyer | Puzzle. |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| SG59988A1 (en) | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| AU759255B2 (en) | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| WO2001000579A1 (en) | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| US6403121B1 (en) | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| GB0021978D0 (en) | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20040013643A1 (en) | 2000-09-19 | 2004-01-22 | Novlmmune S.A. | Methods for treatment of multiple sclerosis with statins |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| EE05472B1 (et) | 2001-01-12 | 2011-10-17 | Fumapharm Ag | Fumaarhappeamiidide kasutamine ravimina |
| GB2373725A (en) | 2001-03-30 | 2002-10-02 | Novartis Ag | Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production |
| EP1390026B1 (en) * | 2001-05-03 | 2010-05-05 | Cornell Research Foundation, Inc. | Treatment of hpv caused diseases |
| FR2825023B1 (fr) | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| PL377403A1 (pl) | 2003-01-29 | 2006-02-06 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania preparatu powlekanego |
| WO2004098510A2 (en) * | 2003-04-30 | 2004-11-18 | Beth Israel Deaconess Medical Center | Cystic fibrosis therapy |
| WO2005023241A1 (en) | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| DE10342423A1 (de) | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| EP1691806A2 (en) | 2003-12-03 | 2006-08-23 | Smithkline Beecham Corporation | Novel therapeutic method and compositions |
| US20050250820A1 (en) | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| CA2571683A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
| ITMI20041825A1 (it) | 2004-09-24 | 2004-12-24 | Medestea Res & Production Srl | Agonisti dei ricettori attivanti la proliferazione dei perossisomi, utili nella prevenzione o nel trattamento della gastrite |
| DK1799196T3 (en) | 2004-10-08 | 2016-08-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
| US20080004344A1 (en) | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
| DE102005022845A1 (de) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
| WO2007006308A1 (en) | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| WO2007042034A1 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| AR058605A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Preparacion solida |
| SI2019671T1 (sl) | 2006-05-05 | 2015-03-31 | The Regents Of The University Of Michigan | Intermediati za pripravo bivalentnih Smac-mimetikov |
| US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| AU2007299920A1 (en) | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| US20100130607A1 (en) | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| LT2653873T (lt) | 2007-02-08 | 2022-10-10 | Biogen Ma Inc. | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| EP2175845A2 (en) | 2007-07-11 | 2010-04-21 | Cardoz AB | New combination for use in the treatment of inflammatory disorders |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| CN104739841B (zh) | 2008-01-11 | 2018-06-01 | 里亚塔医药公司 | 合成三萜类化合物及用以治病之方法 |
| WO2009097997A1 (de) | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| DE102008030023A1 (de) | 2008-06-16 | 2009-12-17 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit |
| GB0913672D0 (en) | 2009-08-05 | 2009-09-16 | Argenta Discovery Ltd | Glitazones |
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| WO2010039529A2 (en) * | 2008-09-23 | 2010-04-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treament of inflammatory disease |
| WO2010040055A2 (en) | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| KR101483203B1 (ko) | 2009-02-13 | 2015-01-15 | 리아타 파마슈티컬즈, 아이엔씨. | 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물 |
| EP3466420A1 (en) | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
| WO2011039175A1 (en) * | 2009-09-29 | 2011-04-07 | Bodo Melnik | Treatment of acne vulgaris, rosacea and androgenetic alopecia and cancer protection in smokers, obesity and diabetes mellitus |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
| AU2010331926B2 (en) | 2009-12-15 | 2014-03-27 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| DK2533634T3 (en) | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
| US8486922B2 (en) * | 2010-04-28 | 2013-07-16 | Chien-Hung Chen | Composition |
| MX390695B (es) | 2010-09-21 | 2025-03-21 | Intekrin Therapeutics Inc | Composiciones farmaceuticas solidas antidiabeticas |
| US20140080795A1 (en) | 2010-11-19 | 2014-03-20 | University Of Rochester | NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction |
| CN102552140B (zh) * | 2011-01-12 | 2013-05-29 | 北京人福军威医药技术开发有限公司 | 罗格列酮的液体组合物 |
| US20140142095A1 (en) | 2011-04-28 | 2014-05-22 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| WO2013022882A1 (en) | 2011-08-08 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Combination therapy for treatment of inflammatory demyelinating disease |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US8865747B2 (en) | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| DK2841445T3 (en) | 2012-04-27 | 2017-09-11 | Reata Pharmaceuticals Inc | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONMETHYL, POLYMORPHE FORMS THEREOF AND PROCEDURES FOR USING IT |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| HK1218510A1 (zh) | 2013-01-30 | 2017-02-24 | Intekrin Therapeutics, Inc. | 用於治療多發性硬化症的PPARγ激動劑 |
| IN2013MU01468A (OSRAM) | 2013-04-22 | 2015-04-17 | Cadila Healthcare Ltd | |
| WO2015130998A1 (en) | 2014-02-28 | 2015-09-03 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| HUE039555T2 (hu) | 2014-04-02 | 2019-01-28 | Minoryx Therapeutics S L | 2,4-tiazolidindion származékok központi idegrendszer rendellenességeinek kezelésében |
| WO2016074684A1 (en) | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
| KR20190064583A (ko) | 2016-09-13 | 2019-06-10 | 인테크린 테라퓨틱스, 아이엔씨. | Chs-131로 다발성 경화증의 치료 |
| US11382889B2 (en) | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| KR20210031867A (ko) | 2018-06-06 | 2021-03-23 | 미노릭스 테라퓨틱스 에스.엘. | 5-[[4-[2-[5-아세틸피리딘-2-일]에톡시]벤질]-1,3-티아졸리딘-2,4-디온 및 이의 염의 용도 |
| SI3801515T1 (sl) | 2018-06-06 | 2025-07-31 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni |
| JP7549344B2 (ja) | 2018-06-06 | 2024-09-11 | ミノリックス セラピューティクス エセ．エレ． | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 |
-
2012
- 2012-10-18 US US13/654,632 patent/US20130158077A1/en not_active Abandoned
- 2012-12-10 SG SG11201403241XA patent/SG11201403241XA/en unknown
- 2012-12-10 EP EP12801539.3A patent/EP2793876B1/en active Active
- 2012-12-10 KR KR1020227033805A patent/KR20220139414A/ko not_active Ceased
- 2012-12-10 JP JP2014547838A patent/JP6132850B2/ja active Active
- 2012-12-10 ES ES12801539T patent/ES2959111T3/es active Active
- 2012-12-10 CN CN201280062704.0A patent/CN103998035B/zh active Active
- 2012-12-10 BR BR112014014809A patent/BR112014014809A2/pt not_active Application Discontinuation
- 2012-12-10 AU AU2012358420A patent/AU2012358420B9/en active Active
- 2012-12-10 KR KR1020147019944A patent/KR102188487B1/ko active Active
- 2012-12-10 CA CA2859635A patent/CA2859635C/en active Active
- 2012-12-10 PH PH1/2014/501029A patent/PH12014501029A1/en unknown
- 2012-12-10 MX MX2014007254A patent/MX2014007254A/es unknown
- 2012-12-10 MX MX2018012169A patent/MX394473B/es unknown
- 2012-12-10 WO PCT/EP2012/074915 patent/WO2013092269A1/en not_active Ceased
- 2012-12-10 EA EA201400729A patent/EA201400729A1/ru unknown
- 2012-12-10 HK HK15101190.9A patent/HK1200711A1/xx unknown
- 2012-12-18 AR ARP120104793A patent/AR089301A1/es unknown
-
2013
- 2013-02-01 US US13/756,687 patent/US20130172391A1/en not_active Abandoned
-
2014
- 2014-06-15 IL IL233134A patent/IL233134A0/en unknown
- 2014-06-19 CL CL2014001639A patent/CL2014001639A1/es unknown
-
2016
- 2016-11-21 US US15/356,766 patent/US10426763B2/en active Active
-
2017
- 2017-09-05 AU AU2017225019A patent/AU2017225019B2/en active Active
-
2019
- 2019-06-25 AU AU2019204493A patent/AU2019204493B2/en active Active
- 2019-08-28 US US16/553,219 patent/US11484530B2/en active Active
-
2021
- 2021-03-03 AU AU2021201390A patent/AU2021201390B2/en active Active
-
2022
- 2022-10-26 US US18/049,652 patent/US12083107B2/en active Active
-
2024
- 2024-09-05 US US18/825,022 patent/US20240423967A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501029A1 (en) | Pharmaceutical compositions comprising glitazones and nrf2 activators | |
| UY34037A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CA2871471C (en) | Dna-pk inhibitors | |
| MX349004B (es) | Nuevos compuestos. | |
| IN2014MN00986A (OSRAM) | ||
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| MX2020001602A (es) | Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo. | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| UY34387A (es) | Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización. | |
| MY163275A (en) | Ibat inhibitors for the treatment of liver diseases | |
| MX2017011778A (es) | Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8). | |
| CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
| MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
| MX2014000142A (es) | Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes. | |
| EP2523678A4 (en) | WNT ANTAGONISTS AND TREATMENT AND SCREENING METHOD THEREFOR | |
| PH12013501255A1 (en) | Anti-notch1 antibodies | |
| UY34616A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| CR20130138A (es) | Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación | |
| BR112012032248A2 (pt) | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. |